


Rotigotine Hydrochloride

Chemical Properties

CAS No. :	125572-93-2
Formula:	C ₁₉ H ₂₆ ClNOS
Molecular Weight:	351.93
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Rotigotine Hydrochloride (N-0924), a dopamine receptor agonist preferring for D3 receptors over D1 and D2, has effective activity of anti-Parkinsonian. Racemic rotigotine hydrochloride is about 50 times as potent as quinpirole, the gold standard D2 agonist.
Targets(IC50)	5-HT Receptor, Adrenergic Receptor, Dopamine Receptor

Solubility Information

Solubility	DMSO: 70 mg/mL (198.9 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.68 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8415 mL	14.2074 mL	28.4147 mL
5 mM	0.5683 mL	2.8415 mL	5.6829 mL
10 mM	0.2841 mL	1.4207 mL	2.8415 mL
50 mM	0.0568 mL	0.2841 mL	0.5683 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Giladi N, Asgharnejad M, Bauer L, Grieger F, Borojerdi B. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. *J Parkinsons Dis.* 2016 Apr 2. [Epub ahead of print] PubMed PMID: 27061066.

Cannas A, Meloni M, Mascia MM, et al. Priapism and Hypersexuality Associated With Rotigotine in an Elderly Parkinsonian Patient: A Case Report. *Clin Neuropharmacol.* 2016 Apr 4. [Epub ahead of print] PubMed PMID: 27046660.

LeWitt PA, Poewe W, Elmer LW, et al. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. *Clin Neuropharmacol.* 2016 Mar-Apr;39(2):88-93.

Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, Goldammer N, Schollmayer E, Schröder H, Winkelmann JW. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. *Am J Kidney Dis.* 2016 Feb 2. pii: S0272-6386(16)00018-4.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481